Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$47.98 USD
+0.02 (0.04%)
Updated Oct 24, 2025 04:00 PM ET
After-Market: $47.97 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRML 47.98 +0.02(0.04%)
Will TRML be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for TRML
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
Other News for TRML
TRML's price falls by 0.02% on October 23, though its technical setup remains stable.
Catalyst Watch: Trump-Xi, Fed meeting, Honeywell spinoff, and Amazon headlines busy earnings week
TRML rises 0.13% on October 22, leaving the technical picture intact
Technical picture remains unchanged for TRML after it falls 0.04% on October 21
Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer